This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Kevin E. Lofton Appointed To Rite Aid Board Of Directors

Rite Aid Corporation (NYSE: RAD) today announced that its Board of Directors has elected Kevin E. Lofton, president and CEO of Catholic Health Initiatives, to the Rite Aid Board.

“We are very pleased to welcome Kevin to our Board,” said Rite Aid’s Chairman, President and CEO John Standley. “Kevin is a widely recognized and well-respected leader in the healthcare industry whose broad knowledge and experience will be beneficial in helping Rite Aid continue to grow our business and develop innovative ways to better serve our customers in a rapidly changing healthcare environment.”

Catholic Health Initiatives is a national health system, based in Englewood, Colo., that operates a full continuum of services from hospitals and long-term care facilities to home health agencies. Lofton joined CHI in 1998 and has held several leadership positions, including chief operating officer, before being named president and CEO in 2003. Prior to joining CHI, Lofton served as the chief executive officer of the University of Alabama Hospital in Birmingham; as chief executive officer of Howard University Hospital, Washington, D.C.; and chief operating officer at University Medical Center, Jacksonville, Fla.

Lofton is also involved with the American Hospital Association (AHA), having served as the 2007 chair of the AHA Board of Directors. Lofton also serves on the boards of Morehouse School of Medicine in Atlanta; Conifer Health Solutions LLC; and Gilead Sciences, Inc.

Lofton earned a bachelor’s degree in management from Boston University and a master’s degree in health administration from Georgia State University.

Rite Aid is one of the nation’s leading drugstore chains with nearly 4,600 stores in 31 states and the District of Columbia. Information about Rite Aid, including corporate background and press releases, is available through Rite Aid’s website at

Copyright Business Wire 2010

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.03 0.21%
FB $116.73 0.00%
GOOG $691.02 0.00%
TSLA $247.54 -0.07%
YHOO $36.59 0.00%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs